are at the highest risk of developing CMV infection. Without preventive strategies, CMV infection occurs in 69% of such patients. 3 Strategies to prevent CMV infection, which include prophylactic administration of antiviral agents for 3-6 months posttransplant and preemptive treatment after viral detection in blood, have been shown to significantly improve posttransplant outcomes.
4-6
International consensus guidelines on CMV prevention in solid organ transplant recipients, which were first made available CMV D+/R− was still an independent risk factor for death-censored graft failure and mortality.
The goal of this study was to examine the effect of CMV serostatus using the OPTN/UNOS database in >50 000 adult deceased donor recipients transplanted between 2010 and 2015. In addition to the main cohort, we performed a paired kidney analysis, which offered a unique opportunity to better assess the impact of CMV serostatus by minimizing biases related to differences in donor characteristics, in >14 000 paired kidney recipients.
| ME THODS

| Study population
We used the UNOS database to select adult patients with end-stage renal disease (ESRD) who received their first deceased donor kidney- and D+/R+ groups are often grouped together as a CMV intermediate-risk group, we also compared transplant outcomes between the D−/R+ and D+/R+ groups (using D−/R+ as a reference group) to see whether there were any differences in transplant outcomes between these 2 groups.
To minimalize donor variability and biases, the "paired kidney cohort" was used. In this paired cohort, we looked at donor and recipient pairs where the donor had 2 recipients and the recipients had different CMV serostatus from each other (1 seronegative and 1 seropositive). The patients were also categorized into 4 groups.
The transplant outcomes of D−/R− were compared with D−/R+ and D+/R+ outcomes were compared with D+/R− in the paired kidney cohort.
| Outcome measures
The outcomes included the cumulative incidence of rejection at 1-year posttransplant, death-censored graft survival (DCGS), and patient survival, which included all-cause mortality and infectionrelated mortality. For kidney graft survival analysis, patients were censored for patient death or at the last follow-up visits reported to UNOS. For patient survival analysis, patients were censored at their last follow-up data to UNOS/OPTN.
| Statistical analysis
Donor, recipient, and transplant characteristics were described using medians with IQR values, or frequencies, where appropriate.
To compare categorical and continuous variables, the χ 2 and KruskalWallis tests were used, respectively. Acute rejection was examined using logistic regression. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) of patient survival and DCGS were calculated by using Cox proportional hazard models. The covariates included were recipient, donor; and transplant-related characteristics as shown in 
| RE SULTS
| Patients
After excluding 676 patients with missing values for donor and/or recipient CMV serostatus, there were 52 394 deceased donor kidney recipients in the main cohort, with a median follow-up time of BMI, body mass index; D−, cytomegalovirus (CMV)-seronegative donor; D+, CMV-seropositive donor; R−, CMV-seronegative recipient; R+, CMVseropositive recipient; ECD, expanded criteria donors.
| Baseline characteristics
Baseline characteristics of the main cohort and the paired kidney cohort are described in Table 1 and Table 2 Induction therapy was similar across all 4 groups.
In the paired kidney cohort in which D−/R− was compared with D−/R+ and D+/R− was compared with D+/R+, patients in the D−/R− group were more likely to be male and white and to have preemptive transplants compared with the D−/R+ group. Similarly, patients in the D+/R− group were more likely to be male and white and to have preemptive transplants and less likely to have diabetes (37.1% in D+/R− vs 41% in D+/R+; P < .001) compared with the D+/R+ group.
| Acute rejection at 1 year after transplant
The cumulative incidence of acute rejection at 1 year was similar across all groups in the main cohort (9.2% in D−/R−, 9.4% in D−/R+, 9.7% in D+/R+, and 9.7% in D+/R−; P = .58). In the paired kidney cohort, the cumulative incidence of acute rejection was similar between the D−/R− and D−/R+ groups (9% vs 9.7%; P = .34) and between the D+/R− and D+/R+ groups (9.8% vs 10.45%; P = .41). CMV serostatus did not have an effect on acute rejection in the unadjusted and multivariable logistic regression models in both the main cohort and the paired kidney cohort (see Table 3 and Table 4 , respectively). 
TA B L E 2 Baseline characteristics according to CMV D/R serostatus in the paired kidney cohort
| Death-censored graft survival
The Kaplan-Meier survival curves for death-censored graft failure according to CMV serostatus are shown in Figure 1 TA B L E 3 Impacts of CMV serostatus on transplant outcomes in the main cohort Table 3 ). When D+/R− was compared with D+/R+, there Table 4 ).
| All-cause mortality
The Kaplan-Meier survival curves for patient survival according to CMV serostatus are shown in Figure 3 model, D+/R− was the only group associated with a significantly greater risk of mortality compared with the D−/R− group (HR = 1.18; 95% CI, 1.07-1.30; P < .001) (see Table 3 ). When comparing D+/R− to D+/R+, the D+/R− group was associated with a greater risk of mortality (HR = 1.10; 95% CI, 1.03-1.17, P = .01 in the univariable model and HR = 1.15; 95% CI, 1.07-1.23; P < .001 in the multivariable model).
In the paired kidney cohort, the D+/R− group was associated with a greater risk of mortality (HR = 1.19; 95% CI, 1.06-1.34, P = .003) in the univariable model compared with D+/R+. This difference persisted after adjusting for recipient, transplant-related factors, and induction immunosuppression in the multivariable model (HR = 1.21; 95% CI, 1.07-1.36, P = .003) (see Table 4 ).
Diabetes was among various variables that were applied in the multivariable model. In the same multivariable model, diabetic status was associated with a greater risk of mortality (HR = 1.77; 95% CI, 1.57-2.01, P < .001). Despite the fact that the D+/R+ group had statistically more patients with diabetes compared with the D+/R− group, D+/R+ was associated with better patient survival, suggesting that the difference in the numbers of patients with diabetes did not impact patient survival in the D+/R+ to D+/ R− comparison.
| Infection-related mortality
Using the D−/R− group as a reference in the main cohort, only the D+/R− group was found to be associated with a greater risk of infection-related mortality in the univariable model (HR = 1.55; 95%
CI, 1.18-2.04; P = .002). In the multivariable model, the D+/R− group continued to be associated with a significantly greater risk of infection-related mortality compared with the D−/R− group (HR = 1.38; 95% CI, 1.04-1.84; P = .03) (see Table 3 ). In the paired kidney cohort, the D+/R− group was associated with a greater risk of infection-re- 
| D−/R+ vs D+/R+
| Thymoglobulin induction and CMV serostatus
Thymoglobulin induction was not statistically associated with all-cause mortality, death-censored graft failure, or infection-related mortality in all multivariable analyses in this study (data not shown). To assess for interaction between CMV serostatus and thymoglobulin induction, an interaction term was created and entered in the multivariable models. In the main cohort, there were no interactions between D−/R− and D+/ R− and ATG (P value for interaction = .30 in patient survival analysis, P value for interaction = .48 in DCGS analysis, and P value for interaction = .48 in infection-related mortality). In the paired kidney cohort, there were also no interactions between D+/R+ and D+/R− and ATG (P value for interaction = .86 in patient survival analysis, and P value for interaction = .39 in DCGS analysis, and P value for interaction = .99 in infection-related mortality).
| D ISCUSS I ON
This analysis, which included 52 394 deceased donor kidney transplants performed in the United States between 2010 and 2015,
demonstrates that CMV D+/R− is still an independent risk factor for a poorer graft and patient survival. In our main cohort, D+/ R− was associated with a 17% higher risk of death-censored graft failure, 18% higher risk of all-cause mortality, and 38% higher risk of infection-related mortality compared with D−/R− despite no difference in rates of early acute rejection. Taking a step further, we undertook a paired kidney analysis in an attempt to create a hypothetical situation to see what happens in the long term if a same deceased donor kidney is allocated to a recipient with a certain CMV serostatus. We found that if a donor with positive CMV serostatus was allocated to a recipient with negative CMV serostatus rather than a recipient with positive CMV serostatus, there was a 21% higher risk of all-cause mortality and 47% higher risk of infection-related mortality despite the fact that recipients with negative CMV serostatus had proportionally more preemptive transplants and less diabetes. CMV infection is known to be associated with an increased risk of mortality. Apart from its direct effect causing tissue-invasive disease, CMV infection is also associated with an increased risk of bacterial infections such as pneumonia and nocardiosis and invasive fungal diseases such as aspergillosis. 14 CMV infection may also play a role in an increased incidence of cardiovascular disease and chronic allograft dysfunction.
15
Although it is well established that posttransplant CMV infection is associated with an increased risk of acute rejection, CMV serostatus was not associated with acute rejection in our study.
Unfortunately, the direct association between CMV infection and acute rejection could not be assessed in our study due to the lack of UNOS data on posttransplant CMV infection. Our finding regarding acute rejection is consistent with Kuo et al, 13 who concluded that CMV seromismatch was no longer a risk factor for acute rejection in the era of widespread CMV prophylaxis. In the era before CMV prophylaxis was widely used, there were 2 studies that showed Unsurprisingly, our results in the main cohort analysis are consistent with that reported by Kuo et al 13 given that both studies were based on the same source of population data. The difference between our study and the study by Kuo et al is the transplant era.
We found that almost a decade later than Kuo et al, in the era when the International Consensus Guideline on CMV Prevention has been widely implemented, 7, 8 CMV D+/R− continues to portend a worse prognosis for patient and kidney allograft. In other words, current CMV preventive strategies are not fully effective enough, highlighting the need for improved strategies for prevention.
Close monitoring of CMV viremia should be performed if noncompliance is suspected or patients cease antiviral prophylaxis prematurely. Because late-onset CMV infection remains common after the period of prophylaxis and continues to negatively impact transplant outcomes, [17] [18] [19] several strategies have been proposed to prevent late-onset CMV infection. These include prolongation of antiviral prophylaxis beyond 6 months 20 or the use of serial viral monitoring after the discontinuation of prophylaxis, which is referred to as a hybrid preemptive/prophylaxis therapy approach. 21 Other novel approaches such as CMV-specific T cell assays and CMV vaccines have been explored in clinical studies. 22, 23 A pretransplant allocation strategy by matching deceased kidney donors and recipients by CMV serostatus is another promising method to prevent CMV infection, mortality, and costs associated with prophylaxis and therapy. 24 serostatus and thymoglobulin induction on these transplant outcomes. These findings imply that avoiding thymoglobulin induction in the D+/R− group does not improve these transplant outcomes. In addition, we found no statistical differences in any transplant outcomes between D−/R+ and D+/R+ groups, which often grouped to-
The study is limited by the use of registry data, particularly the lack of data on whether any kind of CMV prevention was used in individual recipients, medication dosage, and duration of preemptive or prophylaxis strategies. Unlike the study by Kuo et al, 13 define the term "infection-related mortality." As a result, the data on infection-related mortality were entered arbitrarily by individual transplant centers, which could potentially confound our analysis.
Albeit a very low incidence, transfusion-and community-acquired CMV infection might occur in D−/R− recipients who we used as a reference group, which could potentially be another limitation of this analysis.
In conclusion, our findings confirm that CMV D+/R− is still an independent risk factor for death-censored graft failure, all-cause mortality, and infection-related mortality in deceased donor kidney transplant recipients in an era where CMV prophylaxis or preemptive therapy has become the standard of practice. The risk of mortality increases if a kidney from a CMV-seropositive donor is allocated to a CMV-seronegative recipient instead of a CMV-seropositive recipient. Better strategies are needed to prevent CMV infection after kidney transplantation.
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